|
显示项目 458851-458875 / 2307435 (共92298页)
<< < 18350 18351 18352 18353 18354 18355 18356 18357 18358 18359 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2020-02-25T06:12:27Z |
Henry's constants and mass transfer coefficients of halogenated organic pollutants in an air stripping packed column
|
Chiang, P. C.; Hung, C. H.; Mar, J. C.; Chang, E. E.; PEN-CHI CHIANG |
| 臺北醫學大學 |
1998 |
Henry's constants and mass transfer coefficients of halogenated organic pollutants in an air stripping packed column.
|
張怡怡; Chiang PC; Hung CH; Mar JC and Chang EE |
| 臺大學術典藏 |
2018-09-10T04:08:38Z |
Henry's law constant of organic compounds in water from a group contribution model with multipole corrections
|
Lin, S.-T.; S; ler, S.I.; SHIANG-TAI LIN |
| 南華大學 |
2006 |
Henry's Law Constant Variations of Volatile Organic Compounds in Wastewater and Activated Sludge
|
林俊宏;Jun-Hong Lin, Ming-Shean Chou |
| 臺北醫學大學 |
2010 |
HEP Inhibits Lipopolysaccharide-Induced Osteoclastogenesis and Cytokine Synthesis
|
TP, Hsieh;JS, Sun;SY, Sheu |
| 臺北醫學大學 |
2010 |
HEP Inhibits Lipopolysaccharide-Induced Osteoclastogenesis and Cytokine Synthesis
|
Hsieh, TP;Sun, JS;Sheu, SY |
| 東海大學 |
2009-12 |
HEp-2 Cell Classification in Indirect Immunofluorescence Images
|
黃育仁; T. Y. Hsieh, Y. C. Huang, C. W. Chung and Y. L. Huang |
| 東海大學 |
2009-12-08 |
HEp-2 cell classification in indirect immunofluorescence images
|
Hsieh, T.-Y.a , Huang, Y.-C.b , Chung, C.-W.b, Huang, Y.-L.b |
| 東海大學 |
2009-12-08 |
HEp-2 cell classification in indirect immunofluorescence images
|
Hsieh, T.-Y.a , Huang, Y.-C.b , Chung, C.-W.b, Huang, Y.-L.b |
| 東海大學 |
2012-03-19 |
HEp-2 cell images classification based on textural and statistic features using self-organizing map
|
Huang, Y.-C.a , Hsieh, T.-Y.b, Chang, C.-Y.a, Cheng, W.-T.a, Lin, Y.-C.a, Huang, Y.-L. |
| 東海大學 |
2012-03-19 |
HEp-2 cell images classification based on textural and statistic features using self-organizing map
|
Huang, Y.-C.a , Hsieh, T.-Y.b, Chang, C.-Y.a, Cheng, W.-T.a, Lin, Y.-C.a, Huang, Y.-L. |
| 國立成功大學 |
2002-07-29 |
Hepa-1 小鼠細胞蛋白質體如何受2 3 7 8-四氯戴奧辛影響
|
洪千雯; Hung, Chien-Wen |
| 國立臺灣大學 |
2015 |
Heparan Sulfate Modulates Neutrophil and Endothelial Function in Antibacterial Innate Immunity
|
Xu, Ding; Olson, Joshua; Cole, Jason N.; van Wijk, Xander M.; Brinkmann, Volker; Zychlinsky, Arturo; Nizet, Victor; Esko, Jeffrey D.; Chang, Yung-Chi; 張永祺 |
| 臺大學術典藏 |
2000 |
Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7)
|
Wei-Hsuan Yu;Woessner Jr. J.F.; WEI-HSUAN YU; Woessner Jr. J.F. |
| 國立成功大學 |
2009-05 |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu, Chun-Jen; Lee, Po-Huang; Lin, Deng-Yn; Wu, Cheng-Chung; Jeng, Long-Bin; Lin, Pin-Wen; Mok, King-Tong; Lee, Wei-Chen; Yeh, Hong-Zen; Ho, Ming-Chih; Yang, Sheng-Shun; Lee, Ching-Chih; Yu, Ming-Chin; Hu, Rey-Heng; Peng, Cheng-Yuan; Lai, Kuan-Lang; Chang, Stanley Shi-Chung; Chen, Pei-Jer |
| 國立臺灣大學 |
2009 |
Heparanase Inhibitor Pi-88 as Adjuvant Therapy for Hepatocellular Carcinoma after Curative Resection: A Randomized Phase Ii Trial for Safety and Optimal Dosage
|
劉俊人; 李伯皇; 胡瑞恆; 吳誠中; 鄭隆賓; 林炳文; 莫景棠; 葉宏仁; 何明志; 楊勝舜; 陳培哲; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
| 中國醫藥大學 |
2009-02 |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
劉俊人(Chun-Jen Liu); 李伯皇(Po-Huang Lee); 林燈寅(Deng-Yn Lin); 吳誠中(Cheng-Chung Wu); 鄭隆賓(Long-Bin Jeng); 林炳文(Pin-Wen Lin); 莫景棠(King-Tong Mok); 李威震(Wei-Chen Lee); 葉宏仁(Hong-Zen Yeh); 何明志(Ming-Chih Ho); (Sheng-Shun Yang); 李靜枝(Ching-Chih Lee); 游明晉(Ming-Chin Yu); 胡瑞恆(Rey-Heng Hu); 彭成元(Cheng-Yuan Peng); (Kuan-Lang Lai); (Stanley Shi-Chung Chang); 陳培哲(Pei-Jer Chen)* |
| 臺大學術典藏 |
2018-09-10T07:26:51Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu, C.-J. and Lee, P.-H. and Lin, D.-Y. and Wu, C.-C. and Jeng, L.-B. and Lin, P.-W. and Mok, K.-T. and Lee, W.-C. and Yeh, H.-Z. and Ho, M.-C. and Yang, S.-S. and Lee, C.-C. and Yu, M.-C. and Hu, R.-H. and Peng, C.-Y. and Lai, K.-L. and Chang, S.S.-C. and Chen, P.-J.; 劉俊人;李伯皇;胡瑞恆;吳誠中;鄭隆賓;林炳文;莫景棠;葉宏仁;何明志;楊勝舜;陳培哲; LIU, CHUN-JEN;LEE, PO-HUANG;HU, REY-HENG;WU, CHENG-CHUNG;JENG, LONG-BIN;LIN, PIN-WEN;MOK, KING-TONG;YEH, HONG-ZEN;HO, MING-CHIH;YANG, SHENG-SHUN;CHEN, PEI-JER; MING-CHIH HO; PO-HUANG LEE; CHUN-JEN LIU; PEI-JER CHEN; REY-HENG HU; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
| 臺大學術典藏 |
2020-02-19T09:33:57Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:55Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 元培科技大學 |
2002 |
Heparin binding stabilizes the membrane-bound form of cobra cardiotoxin.
|
Sue SC; Chien KY; Huang WN; Abraham JK; Chen KM; Wu WG. |
| 國立臺灣大學 |
2015 |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao, Wei-Yu; Ho, Chao-Chi; Hou, Hsin-Han; Hsu, Tsi-Hsuan; Tsai, Meng-Feng; Chen, Kuan-Yu; Chen, Hsuan-Yu; Lee, Yung-Chie; Yu, Chong-Jen; Lee, Chau-Hwang; Yang, Pan-Chyr; 楊泮池; 廖唯昱; 陳冠宇; 余忠仁; 何肇基; 李元麒 |
| 臺大學術典藏 |
2022-06-27T07:01:43Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao W.-Y.; Ho C.-C.; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y.; Chen H.-Y.; Lee Y.-C.; CHONG-JEN YU; Lee C.-H.; Yang P.-C. |
显示项目 458851-458875 / 2307435 (共92298页)
<< < 18350 18351 18352 18353 18354 18355 18356 18357 18358 18359 > >>
每页显示[10|25|50]项目
|
